inHEART Medical, an international healthcare company with offices in France and the United States, has received clearance from the U.S. Food and Drug Administration (FDA) for its new 3D visualization software designed to improve the management of ventricular tachycardia (VT) ablation and other cardiac ablation procedures in the electrophysiology (EP) lab.

The software solution uses a proprietary algorithm to evaluate CT and MRI results and then build an interactive 3D model of the patient’s heart. Physicians can then reference those models before and during cardiac procedures.

According to data presented at European Heart Rhythm Association (EHRA) 2021, using this new software can lead to significant reductions in VT procedure times and higher success rates.

“We have been using the inHEART solution in clinical research for several years. Now with its commercial availability, inHEART will become part of our standard of care for planning and guiding therapeutic interventions,” Jeffrey Winterfield, MD, arrhythmia service chief and cardiac electrophysiology chair at MUSC Health, said in a prepared statement from inHEART. “The detailed substrate information in the 3D models allows us to pinpoint with accuracy and precision the arrhythmogenic areas in the scar tissue and target our ablation strategy accordingly. This information is invaluable for simplifying and enhancing our approach to VT ablation therapy.”